Concentra Group Holdings Parent, Inc. filings document the public reporting of a NYSE-listed occupational health services company with common stock registered under the symbol CON. Recent Form 8-K disclosures cover results of operations and financial condition, Regulation FD presentations, dividend declarations, preliminary operating metrics, and material executive and compensation matters.
The company's proxy and annual-meeting filings disclose board elections, advisory executive compensation votes, auditor ratification, stockholder voting results, and governance procedures. Other filings describe executive equity awards under the 2024 Equity Incentive Plan, leadership succession disclosures, and the company's Delaware corporate and capital-stock structure.
Concentra Group Holdings Parent, Inc. (CON) officer Michael A. Kosuth, identified as Executive Vice President, Chief Operating Officer - East, received a grant of 53,191 shares of restricted stock on November 3, 2026. His reported direct common-stock holdings after the grant were 166,742 shares.
Concentra Group Holdings Parent, Inc. (CON) Executive Vice President and Chief Operating Officer, Onsite Health & Telemedicine, Michael D. Rhine acquired 43,883 shares of restricted stock on November 3, 2026, bringing his directly held shares to 120,046. The transaction is a restricted-stock grant, not a reported market purchase.
Concentra Group Holdings Parent, Inc. (CON) director Marc R. Watkins acquired 3,989 shares of common stock as a grant of restricted stock on November 3, 2026. His directly held common stock position after the grant was 24,729 shares. The restricted stock will vest in full on November 3, 2027, subject to certain exceptions.
Concentra Group Holdings Parent, Inc. director Robert A. Ortenzio acquired 3,989 shares of restricted stock on November 3, 2026. The award is scheduled to vest in full on November 3, 2027, subject to certain exceptions. His reported direct holdings after the award were 4,667,783 shares. Reported indirect holdings included 882,115 shares in the Robert A. Ortenzio Descendants Trust; 196,286 shares in each of the Robert A. Ortenzio 2014 Trust for Kevin M. Ortenzio and the Robert A. Ortenzio 2014 Trust for Bryan A. Ortenzio; 206,286 shares in the Robert A. Ortenzio 2014 Trust for Madeline G. Ortenzio; and 503,455 shares in the Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio.
Concentra Group Holdings Parent, Inc. (CON) reports that Executive Vice President, Chief Marketing and Innovation Officer Thomas A. Devasia acquired 41,223 shares of restricted stock as a grant on November 3, 2026. His direct holdings following the grant were 155,320 shares.
Concentra Group Holdings Parent, Inc. (CON) reports that Executive Vice President and Chief Legal Counsel Timothy F. Ryan acquired 46,543 shares of restricted stock on November 3, 2026. His reported direct holding after the transaction was 160,640 shares. The transaction was a grant/award acquisition, not a market purchase.
Concentra Group Holdings Parent, Inc. director Vipin Gopal acquired a 3,989-share restricted stock award on November 3, 2026. The award is held directly and, subject to certain exceptions, will vest in full on November 3, 2027.
Concentra Group Holdings Parent, Inc. (CON) reported third-quarter revenue of $622.1 million, up 8.6% from $572.8 million. Net income attributable to the company was $65.9 million, versus $48.3 million, and diluted earnings per share were $0.52, versus $0.38. Adjusted EBITDA was $140.2 million, versus $118.9 million. For the first nine months, revenue was $1,797.7 million, up 10.7%, and net income attributable to the company was $181.7 million, versus $131.7 million.
Quarterly patient visits increased 4.9% to 3,731,956; management attributed revenue growth primarily to organic increases in visits and revenue per visit. The 2025 acquisitions of Nova Medical Centers and Pivot Onsite Innovations also contributed to nine-month revenue. Nine-month operating cash flow was $208.1 million, versus $160.7 million. At September 30, 2026, cash was $85.8 million and revolving-credit availability was $430.3 million; Concentra made $50.0 million in voluntary term-loan prepayments during the quarter.
After quarter-end, the board authorized a new share repurchase program of up to $250 million with no expiration date; the authorization does not require repurchases. It also declared a $0.0625-per-share dividend payable on or about December 4, 2026, to holders of record November 19, 2026.
Concentra Group Holdings Parent, Inc. director William Keith Newton acquired 138,812 shares of restricted stock on November 3, 2026. The award vests in equal annual installments over four years. His directly held common stock position following the award was 532,562 shares. A separate holding entry lists 89,081 shares held indirectly by the Cynthia Lee Newton Beneficiary Trust.
Concentra Group Holdings Parent, Inc. (CON) EVP & Chief Financial Officer Raymond Tanner Newton received a grant of 55,851 shares of common stock on November 3, 2026. The award is restricted stock that will vest in equal annual installments over four years.